Ranolazine-d5

CAT: 0804-HY-B0280SSize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-B0280SSize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) [1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
CAS Number
[1092804-87-9]
Product Name Alternative
CVT 303-d5; RS 43285-003-d5
UNSPSC
12352005
Target
Calcium Channel; Isotope-Labeled Compounds; Sodium Channel
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling; Others
Field of Research
Cardiovascular Disease; Cancer
Solubility
10 mM in DMSO
Smiles
CC(C=CC=C1C)=C1NC(CN(CC2)CCN2C([2H])([2H])C(O)([2H])C([2H])([2H])OC3=C(C=CC=C3)OC)=O
Molecular Formula
C24H28D5N3O4
Molecular Weight
432.57
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73 (1) :55-73.|[3]Wang WQ, et al. Antitorsadogenic effects of ({+/-}) -N- (2,6-dimethyl-phenyl) - (4[2-hydroxy-3- (2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325 (3) :875-81.|[4]Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418 (1-2) :105-10.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported